MOTS-c and Muscle Wasting Models: Immobilization, Unloading, Glucocorticoids and Cachexia in the Research Literature

RESEARCH · MOTS-C 10MG · MUSCLE ATROPHY MODELS

MOTS-c and Muscle Wasting Models: Immobilization, Unloading, Glucocorticoids and Cachexia in the Research Literature

PurixLab’s MOTS-C 10mg product is a lyophilized research vial of MOTS-c, the 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene. Earlier articles in this series covered the basic research overview, exercise and AMPK signalling and circulating levels in human observational studies. This overview narrows in on a different cluster of papers: laboratory models of muscle wasting rather than muscle performance, where muscle is lost to immobilization, unloading, glucocorticoid exposure, tumour burden or kidney disease. All PurixLab material is for laboratory research use only.

Why wasting models are a separate question

The peptide was first described as a regulator of metabolic homeostasis that acts largely on skeletal muscle, inhibiting the folate cycle and de novo purine biosynthesis and activating AMPK in vitro and in mouse models [1]. A later study reported that treatment enhanced physical performance in young, middle-aged and old mice and regulated nuclear genes tied to metabolism and proteostasis, with exercise inducing endogenous expression in human skeletal muscle and in circulation [2]. Those findings concern capacity and homeostasis in otherwise healthy tissue. Catabolic models ask something narrower: when a defined insult drives protein breakdown, do the same pathways still move, and is muscle mass actually preserved?

Atrophy signalling: myostatin and the FOXO axis

A 2021 report connected the peptide to myostatin, a negative regulator of muscle mass. The authors reported that plasma MOTS-c levels were inversely correlated with myostatin levels in human subjects, that treatment prevented palmitic-acid-induced atrophy in differentiated C2C12 myotubes, and that treatment lowered plasma myostatin in diet-induced obese mice [3]. Mechanistically they described increased AKT phosphorylation inhibiting the upstream transcription factor FOXO1, with CK2, PTEN and mTORC2 upstream of AKT [3]. That places the peptide on the same signalling axis the atrophy literature already uses, which is why several groups then tested it against a physical insult rather than a metabolic one.

Immobilization and unloading

In a cast-immobilization model in male C57BL/6J mice, immobilization reduced muscle mass by about 15%, while the treated group lost only about 5% [4]. The authors reported normalized phospho-AKT, phospho-FOXO1 and phospho-FOXO3a levels, lower circulating inflammatory cytokines including IL-1β, IL-6, CXCL1 and MCP-1, and RNA sequencing changes in adipogenesis-modulating genes within the PPAR pathway, with lower muscle fatty acid levels than in casted controls [4]. Their interpretation was that limiting lipid infiltration is part of the effect.

A rat hindlimb-suspension study took a functional angle. After 7 days of unloading, the treated soleus did not show the increased fatigue seen in placebo animals in an ex vivo fatigue test, and immunohistochemistry indicated that the slow-to-fast fibre transformation was prevented and atrophy of slow fibres (but not fast fibres) was mitigated [5]. The authors also reported preserved AKT and GSK3β phosphorylation, control-level 18S and 28S rRNA, and reduced MuRF and Atrogin-1 mRNA relative to the placebo unloading group [5]. The fibre-type selectivity is worth noting: an effect confined to slow oxidative fibres is a narrower claim than “prevents atrophy”.

Human myotubes and glucocorticoid-driven wasting

Work in primary human myotubes tested the peptide against dexamethasone, a glucocorticoid that reliably drives wasting in culture. Dexamethasone decreased myotube area and the fusion index and raised MURF1, MAFbx and PGC1α; co-treatment with MOTS-c preserved myotube area and fusion index, increased AKT phosphorylation, and blunted both MURF1 upregulation and STAT3 activation compared with dexamethasone alone [6]. S14G-humanin, tested in parallel, preserved area and blunted STAT3 activation but did not change the fusion index or E3 ligase mRNA levels [6]. This is one of the few datasets in human muscle cells rather than rodent tissue, and it suggests the two mitochondrial-derived peptides are not interchangeable in this model.

The same group looked at endogenous levels in people. In 19 physically active men who trained for four weeks and then had one ankle immobilized for two weeks, immobilization itself did not change mitokine levels; repeated heat exposure raised circulating MOTS-c and lowered skeletal muscle FGF21, while immobilization reduced gastrocnemius medialis thickness and cross-sectional area [7]. In other words, the insult that caused measurable muscle loss did not by itself move the peptide, which complicates any simple reading of circulating levels as a wasting biomarker.

Tumour-bearing models

Cancer cachexia is a harder test because wasting is systemic. In mice inoculated with Colon-26 carcinoma cells, treatment did not prevent total body weight or fat loss, but quadriceps weight was preserved relative to tumour-bearing vehicle controls, with a trend toward protection of gastrocnemius mass [8]. The authors reported attenuated cachexia-induced upregulation of Atrogin-1 and MuRF1, increased inhibitory pFOXO1, reduced pFOXO3a and partial restoration of PGC-1α protein, alongside raised PGC-1α mRNA and AMPK phosphorylation in treated myotubes [8]. The title of that paper says “partially protects”, and the data support exactly that wording: a muscle-specific signal within an animal that was still losing weight.

Human cohorts: kidney disease and dialysis

Observational work points in a consistent direction without establishing cause. In advanced chronic kidney disease, skeletal muscle expression of both humanin and MOTS-c was reported as reduced, with serum MOTS-c also lower, and lower muscle levels associated with lower mitochondrial density and evidence of oxidative stress [9]. A pilot study in 32 chronic peritoneal dialysis patients measured the peptide in serum, urine and dialysate: those at very high sarcopenia risk by the SARC-F tool had lower serum and higher dialysate levels, and serum levels correlated with muscle performance in physical tests [10]. Both are small and cross-sectional, and dialysate clearance is a plausible confounder for the circulating value.

Fibre type and cell model matter

A comparison across two muscle cell lines found divergent responses. In C2C12 cells the peptide increased survival at nanomolar concentrations and stimulated ERK phosphorylation within minutes, promoted differentiation through muscle regulatory factors, and decreased lipid accumulation; none of those differentiation or survival effects appeared in L6 cells, where lipid accumulation instead increased, though proliferation slowed in both lines [11]. Anyone designing an experiment should treat the cell line and fibre type as variables rather than details.

Reading this literature critically

Most of these studies share features that limit how far the results generalise. They are short, they use animal or cell models of wasting rather than clinical disease, treatment is systemic and begins at or before the insult, and the outcome is often a signalling readout rather than function. Mass and signalling do not always agree: the cachexia study preserved a specific muscle without preserving body weight [8], and the unloading study preserved fatigue resistance and slow fibres only [5]. There are no published human clinical trials of MOTS-c for muscle wasting of any cause.

What remains open

Several questions follow directly from the papers above. Whether the AKT-FOXO-E3 ligase axis described in rodents operates the same way in human muscle beyond the single myotube study [6]; whether lowered lipid infiltration is a mechanism or a consequence [4]; why slow fibres and C2C12 cells respond while fast fibres and L6 cells do not [5,11]; whether reduced muscle and serum levels in kidney disease are a cause of muscle loss or a marker of mitochondrial dysfunction [9,10]; and whether the heat-stress route to raising circulating levels has any bearing on muscle outcomes [7]. These are research questions, not established findings.

MOTS-C 10mg: a labelled lyophilized research vial with 10mg per vial, C$54 per vial (CAD, before tax), supplied for laboratory research only. It is not the material used in the studies above. The product page does not currently show a certificate of analysis. If your project needs particular supporting documentation, email [email protected] before ordering and tell us what you need. Product page: purixlab.com/product/mots-c-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout). Current offers are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View MOTS-C 10mg

Questions: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PubMed 25738459 · PMC4350682 · doi:10.1016/j.cmet.2015.02.009
  2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed 33473109 · PMC7817689 · doi:10.1038/s41467-020-20790-0
  3. Kumagai H, Coelho AR, Wan J, et al. MOTS-c reduces myostatin and muscle atrophy signaling. Am J Physiol Endocrinol Metab. 2021;320(4):E680-E690. PubMed 33554779 · PMC8238132 · doi:10.1152/ajpendo.00275.2020
  4. Kumagai H, Kim SJ, Miller B, et al. Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration. Am J Physiol Endocrinol Metab. 2024;326(3):E207-E214. PubMed 38170165 · PMC11196098 · doi:10.1152/ajpendo.00285.2023
  5. Sidorenko DA, Lvova ID, Tyganov SA, et al. The impact of mitokine MOTS-c administration on the soleus muscle of rats subjected to a 7-day hindlimb suspension. J Muscle Res Cell Motil. 2025;46(3):215-229. PubMed 40608240 · doi:10.1007/s10974-025-09700-3
  6. Elhusseiny R, Ihsan M, Bellefroid T, et al. Mitochondrial-derived peptides MOTS-c and humanin attenuate dexamethasone-induced atrophy in human skeletal muscle cells. Physiol Rep. 2026;14(4):e70791. PubMed 41732124 · PMC12930096 · doi:10.14814/phy2.70791
  7. Elhusseiny R, Ihsan M, Labidi M, et al. Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization. Med Sci Sports Exerc. 2025;57(12):2764-2774. PubMed 40674654 · doi:10.1249/MSS.0000000000003825
  8. Jamnick NA, Livingston PD, Gammon CJ, et al. MOTS-c partially protects against skeletal muscle deterioration in C26 cachexia. Front Med (Lausanne). 2026;13:1838178. PubMed 42266945 · PMC13243040 · doi:10.3389/fmed.2026.1838178
  9. Liu C, Gidlund EK, Witasp A, et al. Reduced skeletal muscle expression of mitochondrial-derived peptides humanin and MOTS-C and Nrf2 in chronic kidney disease. Am J Physiol Renal Physiol. 2019;317(5):F1122-F1131. PubMed 31432706 · doi:10.1152/ajprenal.00202.2019
  10. Zicarelli M, Greco M, Roumeliotis S, et al. MOTS-c Levels and Sarcopenia Risk in Chronic Peritoneal Dialysis Patients: A Pilot Study. Medicina (Kaunas). 2025;61(2):322. PubMed 40005438 · PMC11857303 · doi:10.3390/medicina61020322
  11. Leciejewska N, Pruszyńska-Oszmałek E, Kołodziejski P, et al. MOTS-c Impact on Muscle Cell Differentiation and Metabolism Across Fiber Types. Cell Physiol Biochem. 2025;59(1):34-46. PubMed 39876762 · doi:10.33594/000000755

Leave a Comment

Your email address will not be published. Required fields are marked *